JP2003528604A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003528604A5 JP2003528604A5 JP2001570712A JP2001570712A JP2003528604A5 JP 2003528604 A5 JP2003528604 A5 JP 2003528604A5 JP 2001570712 A JP2001570712 A JP 2001570712A JP 2001570712 A JP2001570712 A JP 2001570712A JP 2003528604 A5 JP2003528604 A5 JP 2003528604A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- adenovirus
- adenovirus vector
- vector according
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000701161 unidentified adenovirus Species 0.000 description 52
- 239000013598 vector Substances 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 33
- 108090000623 proteins and genes Proteins 0.000 description 28
- 108091033319 polynucleotide Proteins 0.000 description 18
- 239000002157 polynucleotide Substances 0.000 description 18
- 102000040430 polynucleotide Human genes 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 108020005029 5' Flanking Region Proteins 0.000 description 4
- 108010061861 Uroplakins Proteins 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001902 propagating effect Effects 0.000 description 3
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 101000808105 Homo sapiens Uroplakin-2 Proteins 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 101000808106 Mus musculus Uroplakin-2 Proteins 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19186100P | 2000-03-24 | 2000-03-24 | |
| US60/191,861 | 2000-03-24 | ||
| PCT/US2001/009224 WO2001072994A2 (en) | 2000-03-24 | 2001-03-21 | Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising the same, and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003528604A JP2003528604A (ja) | 2003-09-30 |
| JP2003528604A5 true JP2003528604A5 (enExample) | 2008-04-24 |
Family
ID=22707193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001570712A Withdrawn JP2003528604A (ja) | 2000-03-24 | 2001-03-21 | ヒト尿路上皮細胞特異的ウロプラキン転写調節配列、ウロプラキン特異的転写調節配列を含むベクター、およびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6852528B2 (enExample) |
| EP (1) | EP1268761B1 (enExample) |
| JP (1) | JP2003528604A (enExample) |
| AT (1) | ATE419338T1 (enExample) |
| AU (2) | AU2001245944B2 (enExample) |
| CA (1) | CA2404085A1 (enExample) |
| DE (1) | DE60137208D1 (enExample) |
| WO (1) | WO2001072994A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998205A (en) * | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US6900049B2 (en) * | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| WO2002024148A2 (en) * | 2000-09-22 | 2002-03-28 | Stem Cell Pharmaceuticals Inc. | Method or treatment of tumors using transforming growth factor-alpha |
| US7459154B2 (en) * | 2002-12-26 | 2008-12-02 | Cell Genesys, Inc. | Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| US8796235B2 (en) * | 2003-02-21 | 2014-08-05 | University Of South Florida | Methods for attenuating dengue virus infection |
| US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| US7709224B2 (en) * | 2003-06-03 | 2010-05-04 | Biosante Pharmaceuticals, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| US20050059613A1 (en) * | 2003-07-08 | 2005-03-17 | Bahram Memarzadeh | Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium |
| US20050186178A1 (en) * | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
| US7482156B2 (en) * | 2003-10-15 | 2009-01-27 | Cell Genesys, Inc. | Hepatocellular carcinoma specific promoter and uses thereof |
| EP1689414A4 (en) | 2003-12-04 | 2009-04-08 | Univ South Florida Res Foundat | POLYNUCLEOTIDES FOR REDUCING GENE EXPRESSION OF THE RESPIRATORY SYNCYTIAL VIRUS |
| JP2010504507A (ja) * | 2006-09-20 | 2010-02-12 | インスティチュート・パスツール・コリア | 細胞におけるターゲットタンパク質候補の発現を検出および／または定量する方法、ならびに小分子モデュレーターのターゲットタンパク質を同定する方法 |
| US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
| US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
| US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
| US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
| US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
| GB2480413B (en) | 2009-02-18 | 2014-12-24 | Univ Wayne State | Method for identifying a subpopulation of mammalian cells with distinctive ribosome translation profiles |
| FR2981662A1 (fr) * | 2011-10-20 | 2013-04-26 | Assist Publ Hopitaux De Paris | Methode de quantification de marqueurs renaux par dosage urinaire. |
| WO2024163823A1 (en) * | 2023-02-02 | 2024-08-08 | Shape Therapeutics Inc. | Tissue-specific enhancers for regulating transcription |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69133333T2 (de) | 1991-08-26 | 2004-07-29 | Baxter Healthcare S.A. | Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken |
| US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
| US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US5824543A (en) * | 1995-06-05 | 1998-10-20 | New York University | Method for expression and isolation of biologically active molecules in urine using a mouse uroplakin-II promoter |
| US6323390B1 (en) * | 1995-06-05 | 2001-11-27 | New York University | Transgenic mouse models for human bladder cancer |
| EP1445322B2 (en) | 1995-06-15 | 2012-06-06 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US6197293B1 (en) | 1997-03-03 | 2001-03-06 | Calydon, Inc. | Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof |
| US6254862B1 (en) | 1997-03-03 | 2001-07-03 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
| JP2002514075A (ja) | 1997-03-03 | 2002-05-14 | セル ジェネシス，インコーポレイティド | 癌胎児性抗原を発現する細胞に特異的なアデノウイルスベクターおよびその使用方法 |
| EP1002103B1 (en) | 1997-08-04 | 2007-10-17 | Cell Genesys, Inc. | A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof |
| US6692736B2 (en) * | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
-
2001
- 2001-03-21 DE DE60137208T patent/DE60137208D1/de not_active Expired - Fee Related
- 2001-03-21 US US09/814,292 patent/US6852528B2/en not_active Expired - Fee Related
- 2001-03-21 AU AU2001245944A patent/AU2001245944B2/en not_active Ceased
- 2001-03-21 CA CA002404085A patent/CA2404085A1/en not_active Abandoned
- 2001-03-21 WO PCT/US2001/009224 patent/WO2001072994A2/en not_active Ceased
- 2001-03-21 EP EP01918927A patent/EP1268761B1/en not_active Expired - Lifetime
- 2001-03-21 AT AT01918927T patent/ATE419338T1/de not_active IP Right Cessation
- 2001-03-21 AU AU4594401A patent/AU4594401A/xx active Pending
- 2001-03-21 JP JP2001570712A patent/JP2003528604A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003528604A5 (enExample) | ||
| He et al. | A simplified system for generating recombinant adenoviruses | |
| US7048920B2 (en) | Recombinant oncolytic adenovirus for human melanoma | |
| Mahot et al. | A novel function for the Epstein–Barr virus transcription factor EB1/Zta: induction of transcription of the hIL-10 gene | |
| US5698443A (en) | Tissue specific viral vectors | |
| CN104212802B (zh) | 一种肿瘤细胞广谱高活性启动子及其用途 | |
| US11078487B2 (en) | Cancer-specific trans-splicing ribozymes and use thereof | |
| Coupeau et al. | Kinetic expression analysis of the cluster mdv1-mir-M9–M4, genes meq and vIL-8 differs between the lytic and latent phases of Marek’s disease virus infection | |
| JP2007525949A (ja) | 自己プロセッシング性ペプチド切断部位を含む細胞特異的複製適格ウィルス・ベクター | |
| Reddy et al. | Porcine adenovirus-3 as a helper-dependent expression vector | |
| Guan et al. | Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector | |
| JP2007508036A (ja) | 肝細胞癌特異的プロモーターおよびその使用 | |
| Barkner et al. | Expression of dihydrololate reductase, and of the adjacent Elb region, in an Ad5-dihydrofolate reductase recombinant virus | |
| JP2007522797A5 (enExample) | ||
| Peter et al. | A novel attenuated replication-competent adenovirus for melanoma therapy | |
| EP1121441A2 (en) | Selectively replicating viral vectors | |
| Everett et al. | Strain-specific rate of shutdown of CMV enhancer activity in murine liver confirmed by use of persistent [E1−, E2b−] adenoviral vectors | |
| JP4402457B2 (ja) | アデノウイルスｅ２後期プロモーターの制御のための、インビトロにおけるｙｂ−１の使用、及び、腫瘍の治療を目的とする医薬の製造のための当該使用を活用した核酸構築物の使用 | |
| JP2009535031A5 (enExample) | ||
| Paul et al. | Recombinant baculovirus as a highly potent vector for gene therapy of human colorectal carcinoma: molecular cloning, expression, and in vitro characterization | |
| Xing et al. | Identification of cis-acting sequences required for selective packaging of bovine adenovirus type 3 DNA | |
| US20040171159A1 (en) | Cell-specific adenovirus vector comprising EBV-specific promoter | |
| US7368553B2 (en) | Alternatively spliced nucleic acid molecules | |
| Matsunaga et al. | Cancer cell-specific gene disruption of VEGF-A using Cas9 | |
| JP6153205B2 (ja) | Ｖａ遺伝子破壊アデノウイルスベクターおよびそれを調製するための前駆体ベクター |